High performance liquid chromatographic analysis of MS23 piperidine analog MSP001 in rat plasma

Ting Wang; Desuo Wang

doi:10.1016/j.jpba.2006.05.010

High performance liquid chromatographic analysis of MS23 piperidine analog MSP001 in rat plasma

Ting Wang, Desuo Wang

Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

MSP001 is a newly synthesized piperidine analog of the lead antihypertensive compound MS23 that dually targets cAMP-specific type 4 phosphodiesterase and L-type calcium channels. We validated an analytical protocol for MSP001 in rat plasma using high performance liquid chromatographic method. A C18 column and a phosphate/acetonitrile buffer were used to perform the chromatographic separation. UV detection was carried out at 307 nm, a wavelength at which an absorption peak was detected for this group of compounds. The calibration curve for MSP001 was linear in the range from 25 to 10,000 ng/ml. The limit of quantification (LOQ) was 25 ng/ml. The results demonstrate that this method has high linearity (R = 0.99995), compound specificity, and acceptable precision/accuracy. The protocol is suitable for in vivo pharmacokinetic studies on the compound.

Original language	English (US)
Pages (from-to)	607-612
Number of pages	6
Journal	Journal of Pharmaceutical and Biomedical Analysis
Volume	42
Issue number	5
DOIs	https://doi.org/10.1016/j.jpba.2006.05.010
State	Published - Nov 16 2006

Keywords

Antihypertensive
Dual action
MS23
MSP001
Validation

ASJC Scopus subject areas

Analytical Chemistry
Pharmaceutical Science
Drug Discovery
Spectroscopy
Clinical Biochemistry

Access to Document

10.1016/j.jpba.2006.05.010

Cite this

@article{ab8f08f2b53f47d0b1f5524de701311b,

title = "High performance liquid chromatographic analysis of MS23 piperidine analog MSP001 in rat plasma",

abstract = "MSP001 is a newly synthesized piperidine analog of the lead antihypertensive compound MS23 that dually targets cAMP-specific type 4 phosphodiesterase and L-type calcium channels. We validated an analytical protocol for MSP001 in rat plasma using high performance liquid chromatographic method. A C18 column and a phosphate/acetonitrile buffer were used to perform the chromatographic separation. UV detection was carried out at 307 nm, a wavelength at which an absorption peak was detected for this group of compounds. The calibration curve for MSP001 was linear in the range from 25 to 10,000 ng/ml. The limit of quantification (LOQ) was 25 ng/ml. The results demonstrate that this method has high linearity (R = 0.99995), compound specificity, and acceptable precision/accuracy. The protocol is suitable for in vivo pharmacokinetic studies on the compound.",

keywords = "Antihypertensive, Dual action, MS23, MSP001, Validation",

author = "Ting Wang and Desuo Wang",

year = "2006",

month = nov,

day = "16",

doi = "10.1016/j.jpba.2006.05.010",

language = "English (US)",

volume = "42",

pages = "607--612",

journal = "Journal of Pharmaceutical and Biomedical Analysis",

issn = "0731-7085",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - High performance liquid chromatographic analysis of MS23 piperidine analog MSP001 in rat plasma

AU - Wang, Ting

AU - Wang, Desuo

PY - 2006/11/16

Y1 - 2006/11/16

N2 - MSP001 is a newly synthesized piperidine analog of the lead antihypertensive compound MS23 that dually targets cAMP-specific type 4 phosphodiesterase and L-type calcium channels. We validated an analytical protocol for MSP001 in rat plasma using high performance liquid chromatographic method. A C18 column and a phosphate/acetonitrile buffer were used to perform the chromatographic separation. UV detection was carried out at 307 nm, a wavelength at which an absorption peak was detected for this group of compounds. The calibration curve for MSP001 was linear in the range from 25 to 10,000 ng/ml. The limit of quantification (LOQ) was 25 ng/ml. The results demonstrate that this method has high linearity (R = 0.99995), compound specificity, and acceptable precision/accuracy. The protocol is suitable for in vivo pharmacokinetic studies on the compound.

AB - MSP001 is a newly synthesized piperidine analog of the lead antihypertensive compound MS23 that dually targets cAMP-specific type 4 phosphodiesterase and L-type calcium channels. We validated an analytical protocol for MSP001 in rat plasma using high performance liquid chromatographic method. A C18 column and a phosphate/acetonitrile buffer were used to perform the chromatographic separation. UV detection was carried out at 307 nm, a wavelength at which an absorption peak was detected for this group of compounds. The calibration curve for MSP001 was linear in the range from 25 to 10,000 ng/ml. The limit of quantification (LOQ) was 25 ng/ml. The results demonstrate that this method has high linearity (R = 0.99995), compound specificity, and acceptable precision/accuracy. The protocol is suitable for in vivo pharmacokinetic studies on the compound.

KW - Antihypertensive

KW - Dual action

KW - MS23

KW - MSP001

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=33750329605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750329605&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2006.05.010

DO - 10.1016/j.jpba.2006.05.010

M3 - Article

C2 - 16815662

AN - SCOPUS:33750329605

SN - 0731-7085

VL - 42

SP - 607

EP - 612

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

IS - 5

ER -

High performance liquid chromatographic analysis of MS23 piperidine analog MSP001 in rat plasma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this